Research and development daily Intercept Obey cholicacid treatment NASH in the U.S. market cold.

Roche announces the latest developments in the development of type A haemophilia Gene therapy continues to maintain coagulation factor levels; liglitin is proven in adult sepsis in adults with type 2 diabetes in Asia; and Keytruda has been approved by the FDA for first-line single-drug treatment for specific colorectal cancer patientsWe focus on the latest developments in pharmaceutical research and development, to provide research and development personnel with timely and accurate information referencetoday, Roche announced that it will announce the latest research progress on a number of treatments for type A haemophilia at the annual meeting of the International Association for Thrombosis and Hemophilia in JulyThe latest data showed a 91 per cent reduction in the annual haemorrhage rate in patients, and no evidence of a decrease in the expression of coagulation factor VIII was found over two years of follow-upMoreover, no patients were found to have coagulation factor VIII inhibitors, The Results of CheckMate-870 were presented at the American Association for Cancer Research's annual meeting onlineThe study confirmed that the 240 mg fixed dose of 30 minutes infusion was safe and reliable in patients with advanced or metastatic non-small cell lung cancer, mainly in Chinese groups, Verve Therapeutics presented the results of its CRISPR-based monobase editing therapy in non-human primates at the 2020 meeting of the International Society for Stem Cell ResearchThe experiment is the first to show that the use of monobase editing therapy can shut down genes that cause elevated LDL cholesterol and triglycerides through a single treatmentRev Immune,, recently announced that it has launched a Phase II trial for the treatment of new coronary pneumoniaThe purpose of the treatment with CYT107 is to significantly increase the number of immune T cells and correct immune failureBollinger Ingham released the results of the Asian subgroup of CAROLINA's ® Cardiovascular Outcomes Trial, focusing on adult patients with type 2 diabetes with increased cardiovascular riskThe results showed that liglitin did not increase the cardiovascular risk of the Asian population compared to Gremetine and was consistent with the results of the CAROLINA ® study population as a wholerecently, Nocheng Jianhua announced that it completed the first patient in the first phase of a phase 2 clinical study on the treatment of urinary skin cancer in the pan-FGFR inhibitor ICP-192on29, Vitrac Therapeutics, a subsidiary of Jetta, announced the launch of a global clinical trial of Aurora A kinase inhibitor VIC-1911 Today, the U.S FDA announced that it has approved the development of merchadon's heavy PD-1 inhibitor Keytruda Extended Indications, a first-line treatment for patients with non-removable or metastatic microsatellite instability or mismatched repair defects for colorectal cancer patients today, Roche announced that Japan's Ministry of Health, Labour and Welfare has approved the launch of Enspryng, an IL-6 receptor inhibitor developed by the company to prevent the recurrence of disease in adults and children with optic neurospinal itis spectrum disorders 29, Intercept Pharmaceuticals announced that it has received a full response from the U.S FDA regarding the application of its FXR agonisant obeycholic acid for the use of new drug fibrosis caused by non-alcoholic fatty hepatitis (NASH) 29, the FDA approved Roche's antibody cocktail therapy Phesgo to market, subcutaneous injection to treat adult HER2 plus metastatic breast cancer as well as early HER2 plus breast cancer The latest announcement of CDE, Roche is in the study of a new class 1 drug PI3K alpha-specific inhibitor GDC-0077 in China declared clinical trials, and received acceptance 29, GlaxoSmithKline (GSK) announced that Japan's Ministry of Health, Labour and Welfare has approved the application for a new drug in Japan for Duvroq (daprodstat) tablet, an oral hypoxic-induced factor, luxydase inhibitor, for the treatment of anemia patients with chronic kidney disease Novo Nordisk recently announced that Japan's Ministry of Health, Labour and Welfare has approved Rybelsus tablets for the treatment of adult patients with type 2 diabetes 29, Novartis announced that its five new drugs have been approved by Japan's Ministry of Health, Labour and Welfare Tabrecta, Entresto, Mayzent, Enerzair, Atectura, respectively 30, NMPA official website shows that Huahai Pharmaceutical Sau-Ping-kou collapse tablets were approved for listing, the approval number for the National Drug Code H20203281, the National Drug Code H20203282 29, Xinhua Pharmaceuticals announced that the company's kramycin tablets (0.25g) through the consistency evaluation 30, NMPA official website shows that Collum Pharmaceuticals' acetic acid tofati cloth tablets were approved for listing, the approval number of the National Drug Code H20203280, become the third domestic today, Xinlitai 2 class 1 new drugs in the domestic clinical application was accepted, respectively, Ennasta tablets and recombinant human neuromodulation protein 1- anti-HER3 antibody fusion protein injection (project code: SAL007).